X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (21467) 21467
Newsletter (527) 527
Newspaper Article (230) 230
Magazine Article (198) 198
Book Chapter (20) 20
Transcript (17) 17
Book / eBook (6) 6
Book Review (6) 6
Conference Proceeding (4) 4
Dissertation (4) 4
Web Resource (4) 4
Reference (2) 2
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (18876) 18876
hypoglycemic agents - therapeutic use (11592) 11592
male (10186) 10186
female (9958) 9958
diabetes mellitus, type 2 - drug therapy (9745) 9745
hypoglycemic agents - adverse effects (9320) 9320
diabetes (7241) 7241
middle aged (7161) 7161
endocrinology & metabolism (6515) 6515
type 2 diabetes (6028) 6028
hypoglycemic agents - administration & dosage (5776) 5776
aged (5535) 5535
adult (5138) 5138
insulin (5008) 5008
hypoglycemic agents (4294) 4294
glucose (3800) 3800
treatment outcome (3708) 3708
blood glucose - metabolism (3532) 3532
risk factors (3470) 3470
metformin (3373) 3373
animals (3293) 3293
diabetes mellitus, type 2 - blood (3273) 3273
insulin - therapeutic use (3186) 3186
hypoglycemic agents - pharmacology (3013) 3013
diabetes mellitus (2997) 2997
pharmacology & pharmacy (2976) 2976
care and treatment (2795) 2795
diabetes therapy (2781) 2781
blood glucose - drug effects (2712) 2712
glycemic control (2682) 2682
insulin - administration & dosage (2458) 2458
drug therapy (2425) 2425
research (2373) 2373
metformin - therapeutic use (2370) 2370
insulin - adverse effects (2363) 2363
hypoglycemia - chemically induced (2342) 2342
hypoglycemia (2321) 2321
medicine, general & internal (2261) 2261
mellitus (2193) 2193
hyperglycemia (2135) 2135
diabetes mellitus, type 2 - complications (2108) 2108
analysis (2099) 2099
diabetes mellitus, type 1 - drug therapy (2067) 2067
insulin resistance (2065) 2065
glycated hemoglobin a - metabolism (2041) 2041
drug therapy, combination (2037) 2037
diabetes mellitus - drug therapy (2005) 2005
risk (1933) 1933
therapy (1931) 1931
internal medicine (1756) 1756
health aspects (1746) 1746
mortality (1705) 1705
double-blind method (1613) 1613
dextrose (1611) 1611
metformin - adverse effects (1595) 1595
clinical trials (1585) 1585
adolescent (1560) 1560
double-blind (1557) 1557
blood glucose - analysis (1522) 1522
medicine & public health (1434) 1434
time factors (1412) 1412
glycated hemoglobin a - analysis (1405) 1405
abridged index medicus (1349) 1349
safety (1328) 1328
obesity (1313) 1313
management (1291) 1291
dosage and administration (1289) 1289
aged, 80 and over (1275) 1275
retrospective studies (1272) 1272
rats (1251) 1251
thiazolidinediones - therapeutic use (1231) 1231
type 2 diabetes mellitus (1210) 1210
young adult (1201) 1201
dose-response relationship, drug (1169) 1169
thiazolidinediones (1156) 1156
diabetics (1150) 1150
efficacy (1148) 1148
blood sugar (1142) 1142
administration, oral (1132) 1132
thiazolidinediones - adverse effects (1131) 1131
complications and side effects (1121) 1121
hypoglycemic agents - pharmacokinetics (1120) 1120
insulin-resistance (1109) 1109
diabetes mellitus, type 2 - metabolism (1105) 1105
drug administration schedule (1093) 1093
body mass index (1064) 1064
randomized controlled trials as topic (1048) 1048
medical research (1013) 1013
patients (1008) 1008
type 1 diabetes (1007) 1007
metformin - administration & dosage (988) 988
rosiglitazone (988) 988
mice (986) 986
studies (981) 981
diabetes mellitus, type 1 - blood (977) 977
glycosylated hemoglobin (975) 975
glucagon-like peptide-1 (970) 970
insulin - blood (970) 970
insulin - analogs & derivatives (947) 947
hypoglycemia - prevention & control (942) 942
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21131) 21131
German (437) 437
French (243) 243
Japanese (181) 181
Spanish (153) 153
Italian (71) 71
Dutch (57) 57
Russian (54) 54
Danish (39) 39
Czech (38) 38
Chinese (36) 36
Hungarian (35) 35
Polish (34) 34
Norwegian (32) 32
Swedish (32) 32
Portuguese (18) 18
Finnish (8) 8
Hebrew (6) 6
Romanian (4) 4
Turkish (4) 4
Slovak (3) 3
Croatian (2) 2
Korean (2) 2
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 4, pp. 792 - 800
Summary Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug... 
Gastroenterology and Hepatology | Boceprevir | Hepatitis C virus infection | Telaprevir | Pharmacokinetics | Drug interactions | CHRONIC HEPATITIS-C | GASTROENTEROLOGY & HEPATOLOGY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hepatitis C, Chronic - metabolism | Antiviral Agents - pharmacokinetics | Hypnotics and Sedatives - adverse effects | Humans | Hypnotics and Sedatives - administration & dosage | Drug Interactions | Hypoglycemic Agents - administration & dosage | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Cardiovascular Agents - administration & dosage | Anti-Infective Agents - adverse effects | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Opiate Substitution Treatment - adverse effects | Buprenorphine - administration & dosage | Anti-Infective Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Buprenorphine - adverse effects | Antidepressive Agents - administration & dosage | Immunosuppressive Agents - adverse effects | Methadone - administration & dosage | Methadone - adverse effects | Antidepressive Agents - adverse effects | Cardiovascular Agents - adverse effects | Hypoglycemic Agents - adverse effects | Hepatitis C virus
Journal Article
European Journal of Internal Medicine, ISSN 0953-6205, 2014, Volume 25, Issue 10, pp. 900 - 908
Abstract Background Patients with chronic diseases often receive multiple medications and are associated with increased vulnerability to medication errors.... 
Internal Medicine | Safety management/organization and administration | High-alert medications | Patient safety | Chronic patient | Medication errors/prevention and control | EMERGENCY-DEPARTMENT VISITS | HOSPITAL ADMISSIONS | UNIT | ADVERSE DRUG EVENTS | SAFETY | RISK | PREVALENCE | CARE | OLDER PERSONS | MEDICINE, GENERAL & INTERNAL | PRESCRIPTIONS | Digoxin - adverse effects | Drug-Related Side Effects and Adverse Reactions - prevention & control | Antipsychotic Agents - adverse effects | Humans | Sodium Potassium Chloride Symporter Inhibitors - adverse effects | Mineralocorticoid Receptor Antagonists - adverse effects | Amiodarone - analogs & derivatives | Adrenal Cortex Hormones - adverse effects | Amiodarone - adverse effects | Cytostatic Agents - adverse effects | Methotrexate - adverse effects | Analgesics, Opioid - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anticonvulsants - adverse effects | Anti-Arrhythmia Agents - adverse effects | Adrenergic beta-Antagonists - adverse effects | Immunosuppressive Agents - adverse effects | Benzodiazepines - adverse effects | Spironolactone - analogs & derivatives | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Spironolactone - adverse effects | Chronic Disease - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Drugs | Chronic diseases
Journal Article
Inflammopharmacology, ISSN 1568-5608, 2010, Volume 19, Issue 5, pp. 245 - 254
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 09/2013, Volume 33, Issue 9, pp. 2252 - 2260
OBJECTIVE—Experimental evidence suggests that exenatide, a glucagon-like peptide 1 receptor analogue, has significant cardiovascular protective effects in various conditions... 
magnetic resonance imaging | percutaneous coronary intervention | reperfusion injury | myocardial infarction | exenatide | SURVIVAL | RAT | HEART-FAILURE | SIZE | ISCHEMIA | GLUCAGON-LIKE PEPTIDE-1 | PERIPHERAL VASCULAR DISEASE | DYSFUNCTION | HEMATOLOGY | STRAIN | OCCLUSION | Myocardial Infarction - blood | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Myocardial Contraction - drug effects | Male | Peptides - administration & dosage | Troponin I - blood | Cardiotonic Agents - therapeutic use | Myocardial Infarction - therapy | Hypoglycemic Agents - administration & dosage | Time Factors | Cardiotonic Agents - adverse effects | Injections, Subcutaneous | Myocardial Infarction - pathology | Echocardiography, Doppler | Venoms - administration & dosage | Female | Myocardial Infarction - physiopathology | Republic of Korea | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Venoms - adverse effects | Ventricular Function, Left - drug effects | Proportional Hazards Models | Stroke Volume - drug effects | Myocardium - pathology | Treatment Outcome | Biomarkers - blood | Chi-Square Distribution | Magnetic Resonance Imaging | Myocardium - enzymology | Cardiotonic Agents - administration & dosage | Venoms - therapeutic use | Creatine Kinase, MB Form - blood | Aged | Hypoglycemic Agents - adverse effects | Percutaneous Coronary Intervention - adverse effects | Peptides - adverse effects | Peptides - therapeutic use
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2017, Volume 2017, Issue 2, p. CD009966
...‐transplant and diabetes‐related complications. The safety and efficacy of glucose‐lowering agents after kidney transplantation is largely unknown... 
Glomerular diseases | Adamantane | Dipeptidyl Peptidase 4 | Dipeptidyl‐Peptidase IV Inhibitors | Hypoglycemic Agents | Glycated Hemoglobin A | Child health | Glomerular disease | Pyrrolidines | Diabetes Mellitus, Type 1 | Nitriles | Diabetes Mellitus, Type 2 | Sitagliptin Phosphate | Diabetic kidney disease | Kidney disease | Fasting | Pharmacological interventions | Pioglitazone | Graft Survival | Kidney Transplantation | Chronic kidney disease | Hypoglycemia | Insulin | Randomized Controlled Trials as Topic | Vildagliptin | Medicine General & Introductory Medical Sciences | Thiazolidinediones | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | CLINICAL-TRIAL | MORTALITY RISK | BLOOD-GLUCOSE | CARDIOVASCULAR-DISEASE | DOUBLE-BLIND | RENAL-TRANSPLANTATION | RANDOMIZED CONTROLLED-TRIAL | MELLITUS | PATIENT SURVIVAL | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Pyrrolidines - adverse effects | Pyrrolidines - therapeutic use | Thiazolidinediones - therapeutic use | Fasting - blood | Adamantane - therapeutic use | Hypoglycemia - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Thiazolidinediones - adverse effects | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 1 - blood | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Graft Survival - drug effects | Nitriles - adverse effects | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Nitriles - therapeutic use | Sitagliptin Phosphate - adverse effects
Journal Article
Nutrients, ISSN 2072-6643, 2018, Volume 10, Issue 7, p. 921
Diminished bioavailability of nitric oxide (NO), the gaseous signaling molecule involved in the regulation of numerous vital biological functions, contributes... 
Hypertension | Obesity | Watermelon | Liver | Cardiovascular disease | Inflammation | Adipocytes | Endothelial function | Supplements | Enterocytes | Mitochondria | Interventions | Arginine | Nitric oxide | Flow mediated dilation | Therapeutics | Aging | Insulin resistance | Muscle | Diabetes | Immune cells | DEPENDENT DIABETES-MELLITUS | therapeutics | NITRIC-OXIDE SYNTHESIS | L-ARGININE SUPPLEMENTATION | PRESERVED EJECTION FRACTION | enterocytes | HUMAN SKELETAL-MUSCLE | NUTRITION & DIETETICS | arginine | inflammation | muscle | CULTURED ENDOTHELIAL-CELLS | MUSCLE PROTEIN ANABOLISM | watermelon | adipocytes | insulin resistance | obesity | endothelial function | cardiovascular disease | nitric oxide | ORAL L-CITRULLINE | liver | SPONTANEOUSLY HYPERTENSIVE-RATS | mitochondria | immune cells | CHAIN AMINO-ACIDS | supplements | interventions | aging | hypertension | diabetes | flow mediated dilation | Vasodilator Agents - therapeutic use | Hypoglycemic Agents - metabolism | Antioxidants - metabolism | Humans | Citrulline - metabolism | Metabolic Syndrome - metabolism | Antihypertensive Agents - metabolism | Diabetic Angiopathies - physiopathology | Vasodilator Agents - metabolism | Metabolic Syndrome - physiopathology | Hypertension - prevention & control | Metabolic Syndrome - immunology | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Diabetic Angiopathies - prevention & control | Dietary Supplements - adverse effects | Vascular Stiffness | Sarcopenia - metabolism | Endothelium, Vascular - immunology | Hypoglycemic Agents - therapeutic use | Diabetic Angiopathies - metabolism | Sarcopenia - immunology | Endothelium, Vascular - physiopathology | Insulin Resistance | Metabolic Syndrome - therapy | Hypertension - immunology | Citrulline - therapeutic use | Antihypertensive Agents - therapeutic use | Evidence-Based Medicine | Citrulline - adverse effects | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Hypertension - metabolism | Antioxidants - therapeutic use | Sarcopenia - physiopathology | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Endothelium, Vascular - metabolism | Models, Biological | Sarcopenia - prevention & control | Diabetic Angiopathies - immunology | Antioxidants - adverse effects | Vasodilator Agents - adverse effects | Hypoglycemic Agents - adverse effects | Health | Dietary supplements | Muscles | Amino acids | Gastrointestinal tract | Bioavailability | Citrulline | Metabolism | Nitric-oxide synthase | Substrates | Urea | L-citrulline | Synthesis | Gastrointestinal system | Blood pressure | Adults | Supplementation | Age
Journal Article
Food and chemical toxicology, ISSN 0278-6915, 2015, Volume 83, pp. 111 - 124
.... Naturally occurring polyphenols (like curcumin, morin, resveratrol, etc.) have gained importance because of their minimal side effects, low cost and abundance. Curcumin (diferuloylmethane... 
Neurodegenerative disease | Curcumin | Inflammation | Diabetes | Antioxidant | Cancer | OXIDATIVE STRESS | WINGLESS SIGNALING PATHWAY | FOOD SCIENCE & TECHNOLOGY | DOWN-REGULATION | CELL-CYCLE ARREST | ENDOPLASMIC-RETICULUM STRESS | FORKHEAD TRANSCRIPTION FACTORS | ARJUNOLIC ACID | IN-VITRO | RETRACTED ARTICLE. SEE | TOXICOLOGY | NF-KAPPA-B | Neoplasms - metabolism | Neuroprotective Agents - therapeutic use | Arthritis - metabolism | Hypoglycemic Agents - metabolism | Antioxidants - metabolism | Cardiovascular Diseases - prevention & control | Humans | Neurodegenerative Diseases - prevention & control | Neoplasms - prevention & control | Curcumin - metabolism | Neuroprotective Agents - metabolism | Antineoplastic Agents, Phytogenic - metabolism | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Dietary Supplements - adverse effects | Neuroprotective Agents - adverse effects | Antineoplastic Agents, Phytogenic - therapeutic use | Arthritis - prevention & control | Antineoplastic Agents, Phytogenic - adverse effects | Diabetes Complications - prevention & control | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - metabolism | Curcumin - therapeutic use | Diabetes Complications - metabolism | Curcumin - adverse effects | Neurodegenerative Diseases - metabolism | Antioxidants - therapeutic use | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antioxidants - adverse effects | Hypoglycemic Agents - adverse effects | Antioxidants | Polyphenols | Nervous system diseases | Arthritis | Resveratrol | Index Medicus
Journal Article